|Table of Contents|

Expression and clinical significance of FLT3 gene mutations in acute promyelocytic leukemia

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 06
Page:
1011-1015
Research Field:
Publishing date:

Info

Title:
Expression and clinical significance of FLT3 gene mutations in acute promyelocytic leukemia
Author(s):
Zhang Na1; 2; Xiao Min2
1.Department of Hematology,Xijing Hospital of Air Force Medical University,Shaanxi Xi'an 710032,China;2.Department of Hematology,Tongji Hospital,Tongji Medical College of Huazhong University of Science and Technology,Hubei Wuhan 430030,China.
Keywords:
acute promyelocytic leukemia; FLT3-ITD; FLT3-TKD; prognostic significance
PACS:
R733.7
DOI:
10.3969/j.issn.1672-4992.2020.06.030
Abstract:
Objective：To investigate the expression and prognostic value of FLT3-ITD and TKD in acute promyelocytic leukemia (APL).Methods:The DNA was extracted from mononuclear cells of bone marrow in APL patients.The expression of FLT3 gene mutations were examined by PCR,and the results were confirmed by sequencing.Clinical feature and prognosis were analyzed.Results:The incidence of FLT3-ITD and TKD mutations was 29.9% (23/77) and 9.1% (7/77,5 cases with D835Y,1 case with N841I and 1 case with D835Y and D835H).ITD was associated with high WBC count (P=0.033),but TKD was not.Both ITD and TKD mutation had no significant prognostic impact on CR rate and overall survival.However,TKD mutation was tend to indicate decreased event-free survival (P=0.043) and they were both associated with reduced relapse-free survival (FLT3-ITD,P=0.011.FLT3-TKD,P=0.034).In multivariate analysis,FLT3-ITD (HR=6.381,P=0.037),FLT3-TKD (HR=5.198,P=0.009),bone marrow blasts (HR=1.174,P=0.020),WBC>10×109/L (HR=9.067,P=0.011) were adverse factors for RFS.Conclusion:FLT3-ITD and TKD are both expressed in APL.Patients with FLT3-ITD have high WBC.Although FLT3 gene mutations have no significant prognostic impact on CR rate and OS,they can be used as valuable factors to evaluate the risk of relapse in APL.

References:

［1］Sanz MA,Fenaux P,Tallman MS,et al.Management of acute promyelocytic leukemia:Updated recommendations from an expert panel of the European LeukemiaNet ［J］.Blood,2019,133(15):1630-1643.
［2］ Rampal RK,Levine RL.Finding a needle in a haystack:Whole genome sequencing and mutation discovery in murine models［J］.The Journal of Clinical Investigation,2011,121(4):1255-1258.
［3］ Shimada A.Hematological malignancies and molecular targeting therapy［J］.European Journal of Pharmacology,2019（862）:172641.
［4］ Stone RM,Mandrekar SJ,Sanford BL,et al.Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation［J］.The New England Journal of Medicine,2017,377(5):454-464.
［5］ Beitinjaneh A,Jang S,Roukoz H,et al.Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia:A systematic review［J］.Leukemia Research,2010,34(7):831-836.
［6］ Qiu QC,Wang C,Bao XB,et al.The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients［J］.Hematology (Amsterdam,Netherlands),2018,23(3):131-138.
［7］ Lucena-Araujo AR,Coelho-Silva JL,Pereira-Martins DA,et al.Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia［J］.Blood,2019,134(12):951-959.
［8］ Picharski GL,Andrade DP,Fabro A,et al.The impact of Flt3 gene mutations in acute promyelocytic leukemia:A Meta-analysis［J］.Cancers(Basel),2019,11(9):E1311.
［9］ Yoo SJ,Park CJ,Jang S,et al.Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene［J］.Leukemia & Lymphoma,2006,47(9):1788-1793.
［10］ Su L,Li X,Gao SJ,et al.Cytogenetic and genetic mutation features of de novo acute myeloid leukemia in elderly Chinese patients［J］.Asian Pacific Journal of Cancer Prevention:APJCP,2014,15(2):895-898.
［11］ Cicconi L,Divona M,Ciardi C,et al.PML-RARalpha kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy［J］.Leukemia,2016,30(10):1987-1992.
［12］ Fan Y,Cao Y,Bai X,et al.The clinical significance of FLT3 ITD mutation on the prognosis of adult acute promyelocytic leukemia［J］.Hematology (Amsterdam,Netherlands),2018,23(7):379-384.
［13］ Souza Melo CP,Campos CB,Dutra AP,et al.Correlation between FLT3-ITD status and clinical,cellular and molecular profiles in promyelocytic acute leukemias［J］.Leukemia Research,2015,39(2):131-137.
［14］ Breccia M,Loglisci G,Loglisci MG,et al.FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols:Long-term follow-up analysis［J］.Haematologica,2013,98(12):e161-163.
［15］ Iland H,Bradstock K,Seymour J,et al.Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia［J］.Haematologica,2012,97(2):227-234.
［16］ Ablain J,De The H.Retinoic acid signaling in cancer:The parable of acute promyelocytic leukemia［J］.International Journal of Cancer,2014,135(10):2262-2272.
［17］ Molica M,Breccia M.FLT3-ITD in acute promyelocytic leukemia:Clinical distinct profile but still controversial prognosis［J］.Leukemia Research,2015,39(4):397-399.
［18］ Shen Y,Fu YK,Zhu YM,et al.Mutations of epigenetic modifier genes as a poor prognostic factor in acute promyelocytic leukemia under treatment with all-trans retinoic acid and arsenic trioxide［J］.EBio Medicine,2015,2(6):563-571.
［19］ Poire X,Moser BK,Gallagher RE,et al.Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710):Prognostic significance of FLT3 mutations and complex karyotype ［J］.Leukemia & Lymphoma,2014,55(7):1523-1532.

Memo

Memo:
National Natural Science Foundation of China（No.81770211）;国家自然科学基金项目（编号：81770211）
Last Update: 2020-02-10